Voting rights on 31 August 2022

Back

Voting rights on 31 August 2022

- 09 September 2022 - 1 mins read

 This article or press release has no online content. Please download the associated documents for more information.

Attachment

Related Press Releases

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
24 April 2024 7 mins read

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
22 April 2024 5 mins read

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Ipsen publishes its 2023 Universal Registration Document
17 April 2024 4 mins read

Ipsen publishes its 2023 Universal Registration Document
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
08 April 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
02 April 2024 7 mins read

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
07 March 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
15 February 2024 1 mins read

Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
13 February 2024 14 mins read

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
08 February 2024 8 mins read

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital
06 February 2024 1 mins read

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital